<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03961841</url>
  </required_header>
  <id_info>
    <org_study_id>SAHMO202</org_study_id>
    <nct_id>NCT03961841</nct_id>
  </id_info>
  <brief_title>Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma</brief_title>
  <official_title>A Randomised Controlled Trial Comparing Perioperative FLOT, FOLFOX and Preoperative Chemoradiation for Locally Advanced Esophagogastric Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with histologically confirmed esophagogastric junction adenocarcinoma with
      pre-operative staging cT3-4N+M0，aged between 18-75 years old, with adequate organ function
      and having an Eastern Cooperative Oncology Group performance status score ≤2, are randomized
      in a 1:1:1 ratio to receive neoadjuvant chemoradiotherapy with DT46-50Gy plus concomitant
      weekly oxaliplatin and 5-Fu, perioperative chemotherapy of FLOT regimen or FOLFOX regimen.
      The primary end point is disease free survival (DFS), and secondary end point is 5-year
      overall survival (OS), pathological complete remission (pCR) and treatment safety. The final
      study analytics are to be conducted at the end of the 5th year after the last patient's
      enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">August 2029</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 year of disease free survival</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>5 year of overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pathological complete remission</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anastomosis leak rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Esophagogastric Junction Disorder</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Chemoradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>weekly 5-Fu and oxaliplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight perioperative chemotherapy cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve perioperative chemotherapy cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>chemoradiation with weekly 5Fu and oxaliplatin</intervention_name>
    <description>5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week</description>
    <arm_group_label>Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perioperative mFLOT</intervention_name>
    <description>Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles</description>
    <arm_group_label>FLOT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perioperative FOLFOX</intervention_name>
    <description>Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles</description>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consensus of the enrolled patients

          -  from 18 to 75 years old

          -  proven to be primary adenocarcinoma of EGJ

          -  pre-operative staging cT3-4N+M0

          -  no prior other chemotherapy and/or radiation against the disease

          -  normal function of all other vital organs including heart,liver ,kidney and so on

          -  Eastern Cooperative Oncology Group performance status: 0~2

        Exclusion Criteria:

          -  history of other malignancy

          -  allergic reaction to capecitabine or oxaliplatin

          -  enrolled in other clinical trials

          -  abnormal GI tract function

          -  dysfunction of other organs

          -  pregnant or lactating females ,or refuse to receive contraception measures during
             chemotherapy

          -  other situations judged as not adaptive to the study by investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shanshan Li, MD</last_name>
    <phone>86-20-38285497</phone>
    <email>lishsh89@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaohui Zhai, MD</last_name>
    <phone>86-20-38285497</phone>
    <email>zhaixh@zju.edu.cn</email>
  </overall_contact_backup>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jian Xiao</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

